Literature DB >> 19903147

Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis.

Pablo A González1, Susan M Bueno, Claudia A Riedel, Alexis M Kalergis.   

Abstract

Worldwide, Respiratory Syncytial Virus (RSV) causes severe bronchiolitis and pneumonia in children, the elderly and immuno-compromised individuals. Moreover, RSV is the mayor cause of infant hospitalization due to lower respiratory infection, regardless socioeconomic status. Accumulating data support the notion that immune responses elicited against naturally acquired RSV infections are non-lasting and inappropriate for efficient virus clearance. Although there is consensus over the capacity of RSV to impair the development of an effective and protective adaptive immune response, very little is known about specific viral determinants involved in these processes as well as the molecular mechanisms developed by this virus to inhibit T cell function. Recent studies have provided evidence supporting an important role for dendritic cells in RSV-induced suppression of immunity. Although recognized for over 50 years as an important respiratory pathogen and healthcare problem, to date there are no available vaccines against this virus, which highlights the complexity of RSV-induced immunopathology. The development of new prophylactic and therapeutic tools against RSV requires the unveiling of molecular mechanisms and virulence factors responsible for the pathogenesis caused by this virus. In this review, we discuss recent findings describing virulence mechanisms evolved by RSV to negatively modulate the adaptive immune response in the host. Furthermore, novel strategies aimed to induce efficient T cell immunity against RSV are reviewed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903147     DOI: 10.2174/092986709789760724

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  13 in total

1.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

2.  Impaired learning resulting from respiratory syncytial virus infection.

Authors:  Janyra A Espinoza; Karen Bohmwald; Pablo F Céspedes; Roberto S Gómez; Sebastián A Riquelme; Claudia M Cortés; Javier A Valenzuela; Rodrigo A Sandoval; Floria C Pancetti; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

Review 3.  A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.

Authors:  Emma Rey-Jurado; Jorge Soto; Nicolás Gálvez; Alexis M Kalergis
Journal:  Hum Vaccin Immunother       Date:  2017-06-09       Impact factor: 3.452

Review 4.  Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity.

Authors:  Paul M Brown; Dana L Schneeberger; Giovanni Piedimonte
Journal:  Paediatr Respir Rev       Date:  2015-05-23       Impact factor: 2.726

Review 5.  Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design.

Authors:  Janyra A Espinoza; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

6.  Host adaptive immunity deficiency in severe pandemic influenza.

Authors:  Jesus F Bermejo-Martin; Ignacio Martin-Loeches; Jordi Rello; Andres Antón; Raquel Almansa; Luoling Xu; Guillermo Lopez-Campos; Tomás Pumarola; Longsi Ran; Paula Ramirez; David Banner; Derek Cheuk Ng; Lorenzo Socias; Ana Loza; David Andaluz; Enrique Maravi; Maria J Gómez-Sánchez; Mónica Gordón; Maria C Gallegos; Victoria Fernandez; Sara Aldunate; Cristobal León; Pedro Merino; Jesús Blanco; Fernando Martin-Sanchez; Lucia Rico; David Varillas; Veronica Iglesias; Maria Ángeles Marcos; Francisco Gandía; Felipe Bobillo; Begoña Nogueira; Silvia Rojo; Salvador Resino; Carmen Castro; Raul Ortiz de Lejarazu; David Kelvin
Journal:  Crit Care       Date:  2010-09-14       Impact factor: 9.097

Review 7.  Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design.

Authors:  Emma Rey-Jurado; Alexis M Kalergis
Journal:  Int J Mol Sci       Date:  2017-03-04       Impact factor: 5.923

8.  Prenatal Exposure to Respiratory Syncytial Virus Alters Postnatal Immunity and Airway Smooth Muscle Contractility during Early-Life Reinfections.

Authors:  Paul M Brown; Terri J Harford; Vandana Agrawal; Belinda Yen-Lieberman; Fariba Rezaee; Giovanni Piedimonte
Journal:  PLoS One       Date:  2017-02-08       Impact factor: 3.240

Review 9.  Human Respiratory Syncytial Virus: Infection and Pathology.

Authors:  Karen Bohmwald; Janyra A Espinoza; Emma Rey-Jurado; Roberto S Gómez; Pablo A González; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Semin Respir Crit Care Med       Date:  2016-08-03       Impact factor: 3.119

Review 10.  Contribution of IDO to human respiratory syncytial virus infection.

Authors:  Felipe M Benavente; Jorge A Soto; Magdalena S Pizarro-Ortega; Karen Bohmwald; Pablo A González; Susan M Bueno; Alexis M Kalergis
Journal:  J Leukoc Biol       Date:  2019-05-15       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.